HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia

Figure 2

Cell cycle progression analysis after treatment with epigenetic agents in combination with conventional treatment. NB4 and HL60 cells and APL patient promyelocytes were treated with 1 μM Retinoic acid (RA), 2 nM or 8 nM Idarubicin (IDA2 or IDA8), 0.5 μM 3-Deazaneplanocin A (D), and 0.2 μM Belinostat (B) in different combinations; C: untreated cells. (a) Cell cycle distribution was analysed using standard propidium iodide method. (b) Cell cycle inhibition related gene expression changes after treatment were measured using RT-qPCR ΔΔCt method. GAPDH was used as a “housekeeping” gene; results are presented as changes in comparison to untreated cells; results are mean ± S.D. (n = 3); P ≤ 0.05, calculated by one-way ANOVA statistical test.

(a)

(b)